Executive Summary
The 2026-10-21 SEC filing batch is dominated by administrative and procedural disclosures, with a meaningful minority of material developments concentrated in SPAC/de-SPAC financing stress, dilution-prone capital raises, and a handful of strong quantitative prints.
The most material quantitative results were Thermo Fisher's Q3 2026 (revenue $12.14B, up 9% YoY; adjusted operating margin up to 24.5% from 23.3%) and Elevance Health's Q3 2026 (operating revenue up 0.7% YoY, but operating gain flat and Health Benefits operating gain down 27.5%, offset by a raised FY2026 adjusted EPS floor of at least $29.00). Several small-cap and distressed names show clear financing pressure: Banzai's proxy seeks authority to dilute up to $14M at up to a 50% discount, Silicon Valley Acquisition Corp.'s subordinated notes are structurally junior to senior secured financing, and ClimateRock's shareholders' deficit reached $(10.46)M against only $5,370 of cash. Standard BioTools' S-4/A (materiality 9/10) for a reverse merger with Treeline, coupled with Casdin Capital's dual role as a ~23% LAB holder and Treeline investor, is the highest-stakes governance item in the batch. Adial Pharmaceuticals' 10-Q/A (materiality 9/10) shows a Q2 net loss of $51.99M, dominated by a $46.19M acquired IPR&D charge, with stockholders' equity swinging to a $(38.38)M deficit. Across the batch, the 13F filings (Luma, Farnam, Thayer, One River) describe concentrated large-cap holdings but provide no period-over-period comparisons, so portfolio-level trend analysis is not supportable from these documents.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: DEF 14A · 425 · 8-K · DEFA14A · 13F · S-1 · 10-Q
Tracking the trend? Catch up on the prior US SEC Filings Daily Market Digest digest from October 20, 2026.
Investment Signals (11)
- Thermo Fisher Scientific ↓ (BULLISH)▲
Q3 2026 revenue $12.14B, up 9% YoY (6% organic); adjusted EPS $6.68, up 15%; adjusted operating margin expanded to 24.5% from 23.3%; updated 2026 guidance deferred to earnings call
- Elevance Health ↓ (BULLISH)▲
FY2026 adjusted diluted EPS guidance raised to at least $29.00 and diluted EPS to at least $22.00; benefit expense ratio improved 70 bp to 90.6%; nine-month operating cash flow $7.5B vs $4.2B prior year
- Elevance Health ↓ (BEARISH)▲
Q3 operating gain flat at $1.3B, Health Benefits operating gain down 27.5%, medical membership down 1.1% YoY, and nine-month operating margin compressed 120 bp to 3.4% — raised EPS floor rests on a $1.85/share non-operating benefit
- Thermo Fisher Scientific ↓ (BULLISH)▲
Laboratory Products and Biopharma Services grew ~15% YoY to $6,863M, the largest growth contributor, while Specialty Diagnostics fell ~6.5% to $1,098M with segment margin improving to 31.0% from 27.4%
- DRDGOLD ↓ (BULLISH)▲
Q3 2026 revenue up 31% YoY to Rm 2,950.6M, gold sold up 14% YoY, and operating profit up 42% YoY; however operating profit fell 14% QoQ and all-in sustaining costs per oz rose 15% YoY in USD terms
- Adial Pharmaceuticals ↓ (BEARISH)▲
Q2 net loss of $51.99M vs $1.96M prior year, driven by a $46.19M acquired IPR&D charge; cash rose to $28.71M from $5.88M on a $26.8M pre-funded warrant placement, but stockholders' deficit widened to $(38.38)M from positive $5.28M
- ClimateRock ↓ (BEARISH)▲
Q2 2026 net loss narrowed to $124,477 from $172,412 YoY, but current liabilities of $8.23M vs $5,070 of current assets and a $(10.59)M shareholders' deficit signal near-total balance-sheet insolvency
- Artificial Intelligence Technology Solutions (AITX) (BULLISH)▲
Fiscal Q2 2027 revenue $1.99M, up 5% YoY and 8% QoQ; revenue excluding its largest customer rose 61% YoY to a record $1.63M; gross margin fell to 54% including a $271K inventory write-down
- Standard BioTools ↓ (BEARISH)▲
S-4/A for all-stock reverse merger with Treeline Biosciences, with LAB holders owning ~16% and Treeline holders ~84%; concurrent divestitures of mass cytometry and microfluidics businesses to Element Biosystems and ARCHIMED
- HUTCHMED (China) ↓ (BULLISH)▲
Licensing agreement with GSK for KRAS-EGFR antibody conjugate outside China has closed; financial terms are not disclosed in the 6-K body, limiting near-term valuation assessment
- Nuburu, Inc. ↓ (BEARISH)▲
Acquiring 67.1% of Tekne S.p.A. for EUR 5.2M with an earn-out cut from EUR 29.7M to EUR 20.0M; Nuburu has already advanced EUR 27.7M in shareholder loans to Tekne, which faces possible Article 2446/2447 capital-loss measures
Risk Flags (10)
- Banzai International / Dilution↓ [HIGH RISK]▼
Proxy seeks authority to increase authorized shares from 350M to 850M and to issue up to $14M of Class A stock at up to a 50% discount to the Minimum Price; only ~96,724 shares are available for equity plans after accounting for 3,127,184 reserved for warrants
-
Up to $5.0M of unsecured notes (8% cash / 10% PIK) are fully subordinated to senior secured notes, cannot receive principal while senior debt is outstanding, and carry no collateral; initial original principal $2.41M after a 10% OID
- ClimateRock / Solvency↓ [HIGH RISK]▼
Shareholders' deficit widened to $(10,588,448) at Q2 2026 from $(10,292,971) at year-end 2025; Trust Account fell to $103,568 from $160,938 after $60,032 of redemptions, with current liabilities of $8.23M vs $5,070 unrestricted cash
-
Series A convertible preferred of $38.53M recorded as temporary equity, 12.93M potentially dilutive preferred shares, and milestone warrant liability of $23.81M; total liabilities rose to $28.93M from $1.40M
- Nuburu, Inc. / Tekne Recapitalization↓ [HIGH RISK]▼
Tekne's losses as of June 30, 2026 may require urgent equity-strengthening under Italian Civil Code Articles 2446/2447, with Nuburu's EUR 27.7M shareholder loan exposure and EUR 4.0M of deferred consideration through March 2027
- ▼
Largest customer's revenue fell from 46% to 18% of total as it cut spend, loss from operations held at $2.68M for the quarter, and management explicitly flags going-concern risk and reliance on external financing
- Elevance Health / Core Operating Deterioration↓ [MEDIUM RISK]▼
Q3 medical membership fell 1.1% YoY and operating expense rose 9.1%; EPS beat rests on a $1.85/share non-operating benefit rather than core operations
- Standard BioTools / Related-Party Conflict↓ [MEDIUM RISK]▼
Casdin Capital owns ~23% of LAB and is also a Treeline investor, prompting a special committee review; the merger closing is not conditioned on the Element divestiture
- Personalis / Pending Merger Execution↓ [MEDIUM RISK]▼
Pending TempusAI business combination expected to close in late 2026; 401(k) contributions will pause for the remainder of 2026 if closing occurs before year-end, and out-of-the-money options will be cancelled without consideration
-
Subsidiary transferred all Bondly Enterprises shares for HK$1 with no disclosed financial figures for the disposed entity, leaving the impact on the group's results unquantified
Opportunities (8)
- Thermo Fisher Scientific / Guidance Catalyst↓ (OPPORTUNITY)◆
Updated 2026 guidance to be delivered on the earnings call following 9% YoY revenue growth and 15% adjusted EPS growth; margin expansion and divestiture of the microbiology business provide a clean re-rating setup
- Elevance Health / Guidance Momentum↓ (OPPORTUNITY)◆
Raised FY2026 adjusted EPS floor to $29.00 with nine-month operating cash flow of $7.5B (vs $4.2B), supported by improved benefit expense ratio at 90.6%; upside depends on sustaining Medicare Advantage and ACA performance
- DRDGOLD / Gold Price Leverage↓ (OPPORTUNITY)◆
Revenue up 31% YoY and operating profit up 42% YoY, with all-in costs per oz down 19% QoQ; operating leverage to the gold price is visible in the quarter's trend
- Lufax Holding / Earnings Catalyst↓ (OPPORTUNITY)◆
Q3 2026 results scheduled for October 27, 2026, providing a near-term event for a China fintech name with no quantitative figures in the current filing
- Cadeler A/S / Redomiciliation Event-Driven↓ (OPPORTUNITY)◆
Voluntary share exchange offer to move from Denmark to the UK requires >90% tender; the offer expires October 21 unless extended, with a latest possible expiry of December 1, 2026, creating a discrete event-driven window
- Hotel101 Global / Egypt Expansion↓ (OPPORTUNITY)◆
Binding JV for a ~750-room Hotel101-Cairo West (EGP 5.465B / ~US$102.09M) targeting completion by 2029 with WNTR affiliates; project is subject to approvals but expands the brand into its first African market
- Churchill Capital Corp XI / Agility Robotics↓ (OPPORTUNITY)◆
Digit 5 slated for next-year release; company cites $300M of booked multi-year orders and a manufacturing facility built for 10,000 robots per year, with the de-SPAC valuation not yet disclosed
- JinkoSolar / Shareholder Meeting Outcome↓ (OPPORTUNITY)◆
2026 AGM results furnished via press release, though the body lacks financial content, so the catalyst is limited to governance clarity
Sector Themes (6)
- SPAC and De-SPAC Financing Stress◆
Silicon Valley Acquisition Corp., ClimateRock and STARRY SEA ACQUISITION CORP all show structurally subordinated financing, large working-capital deficits or amended governance documents; ClimateRock's shareholders' deficit of ~$(10.5)M and near-zero trust balances highlight that redemption-driven shells rely on related-party loans to survive. Implication: treat SPAC-linked equity as high-dilution, low-recovery exposure until closing terms are finalized.
- Dilution-Driven Capital Raising Among Micro-Caps◆
Banzai (up to $14M at up to 50% discount), Cenntro (ATM offering), Adial (pre-funded warrants and convertible preferred) and Safe & Green/Olenox (Series F convertible preferred consideration) all rely on dilutive instruments. Across these names, funding is coming through equity-linked structures rather than operating cash flow; implication: the dilution overhang is a more reliable forecast than near-term revenue.
- Large-Cap Healthcare Resilience With Operational Strain◆
Thermo Fisher (revenue +9%, adjusted margin +120 bp) and Elevance Health (benefit ratio improved 70 bp, but operating gain flat) show divergence between quality of earnings and headline results. Implication: market rewards margin discipline, but Managed Care operating deterioration deserves separate scrutiny beyond EPS guidance.
- Gold Miners Margin Expansion Under Cost Pressure◆
DRDGOLD's revenue (+31% YoY) and operating profit (+42% YoY) outpaced volume growth (gold sold +14%), while USD all-in sustaining costs per oz rose 15% YoY; this suggests realized price and FX are carrying the margin story rather than unit cost. Implication: sensitivity to the gold price is high relative to cost control.
- Institutional 13F Holdings Concentration in Mega-Caps◆
Luma Capital (~$121.8B across 13 positions), Farnam Financial (58 holdings, ~$135.5M led by Apple and Microsoft), One River (183 entries, heavily options-based) and Thayer Financial (32 holdings, mostly passive ETFs) all show concentration in large-cap technology and index exposures. The filings contain no period-over-period comparisons, so the implication is limited to holdings-level context rather than flow signals.
- Governance Refresh and Board Realignment◆
Entravision added Brian Krzanich and Gary Ferrera (Audit Committee, financial expert designation), Vertical Aerospace appointed Marc Fontaine via a Mudrick Capital director right, and reAlpha set a $100K non-executive director compensation policy. Implication: board changes are primarily activist- or strategy-driven, with Entravision's audit-chair vacancy the item to monitor.
Watch List (8)
- Standard BioTools (LAB)👁
S-4/A amendment filed October 21, 2026 for the Treeline reverse merger; monitor the special committee's review of Casdin Capital's dual role and the timing of the Element and ARCHIMED divestiture closings
- Lufax Holding (LU)👁
Q3 2026 results on October 27, 2026 — first set of quarterly figures following the period with no quantitative data in the current filing
- Elevance Health (ELV)👁
Nine-month operating margin compression (-120 bp) and Health Benefits operating gain decline (-27.5%) to be tracked against the raised FY2026 guidance floor of $29.00 adjusted EPS
-
Voluntary share exchange offer expiring October 21, 2026 unless extended; latest possible expiry December 1, 2026 with a >90% tender threshold
-
Special meeting on October 28, 2026 on the sale transaction; the 650,000-share correction increases outstanding shares to 10,620,883, and Support Parties hold ~26.4% of votes
- Personalis (PSNL) / TempusAI👁
Business combination expected to close late 2026; ESPP offering period ends October 30, 2026, and open enrollment runs November 2–13, 2026
- Banzai International (BNZI)👁
Stockholder vote on authorized share increase to 850M and the $14M Nasdaq 5635(d) financing authorization; any offering must close within three months of approval
- Thermo Fisher Scientific (TMO)👁
Updated 2026 guidance to be issued on the earnings call, following the Q3 print of revenue $12.14B and adjusted EPS $6.68
Filing Analyses
(50)
16-10-2026
Banzai International, Inc. filed a DEF 14A proxy statement seeking stockholder approval for two proposals: (1) an increase in authorized common stock from 350,000,000 to up to 850,000,000 total shares, and (2) authorization under Nasdaq Listing Rule 5635(d) for a potential public offering or financing of up to $14,000,000 of Class A common stock, potentially issued at a discount of up to 50% to the Minimum Price. The filing highlights the company's limited available authorized shares (approximately 96,724 available for equity plans after accounting for outstanding shares and 3,127,184 reserved for warrants), which the Board views as insufficient to support near-term financing needs, indicating dilution risk and liquidity pressure.
- · Proposed offering must be consummated within three months of stockholder approval
- · Company would not enter a transaction constituting a change of control under Nasdaq Listing Rule 5635(b)
- · Abstentions count as votes AGAINST; broker non-votes have no effect on outcome
- · Stockholders have no preemptive rights and no appraisal rights under Delaware law
- · Proposal 2 would permit zero-cash-exercise warrant provisions allowing exchange for shares in excess of the exercise entitlement
- · Company may use the offering to exchange trade debt or settle outstanding liabilities for securities
- · Board may abandon the authorized share amendment even after stockholder approval
19-10-2026
Jasper Therapeutics, Inc. (JSPRW) filed a definitive proxy statement for a virtual special meeting of stockholders on November 13, 2026, seeking approval of Nasdaq-required issuances of voting common stock upon conversion of non-voting preferred stock issued in the completed Kira Pharmaceuticals merger (closed July 16, 2026) and in a related private placement, plus ratification of director Patrick Crutcher's appointment and a possible adjournment proposal. The Board recommends voting FOR all proposals; stockholder approval of the merger itself is not required, and the company has 33,274,561 shares of voting common stock outstanding as of the September 28, 2026 record date.
- · Proposal 1 seeks Nasdaq Listing Rules 5635(a) and 5635(b) approval for common stock issuable on conversion of non-voting Preferred Stock issued in the Kira merger; stockholder approval of the merger itself was not required.
- · Proposal 2 seeks Nasdaq Listing Rule 5635(d) approval for common stock issuable on conversion of Preferred Stock sold in the private placement.
- · Proposal 3 asks stockholders to ratify the appointment of Patrick Crutcher to the Board.
- · Proposal 4 is a contingent adjournment proposal, to be used only if votes are insufficient for Proposals 1, 2 or 3.
- · The Reverse Stock Split has not been effected and no ratio has been selected; share and per-share figures in the proxy are not adjusted for it.
- · Proxy materials are expected to be mailed on or about October 23, 2026; the meeting is virtual at 10:00 a.m. Pacific Time via webcast.
- · Shareholders with questions may contact Alliance Advisors, LLC at 1-866-206-8305 or JSPR@allianceadvisors.com.
21-10-2026
Guardian Metal Resources plc (GMTL) filed a 6-K on October 21, 2026, consisting of an investor-contact and advisory-roster block rather than substantive operating or financial content. The filing lists CEO Oliver Friesen as the principal contact alongside Cairn Financial Advisers LLP (Nominated Adviser), Berenberg and Tamesis Partners LLP (Joint Brokers), and Tavistock (UK) and Edelman Smithfield (US) as financial PR firms. No financial results, amounts, percentages, or operational updates are disclosed in the provided content.
21-10-2026
EigenQ, Inc. and Silicon Valley Acquisition Corp. (SVAQ) disclosed under Rule 425 an unsecured subordinated financing of up to $5.0 million from a special purpose investment vehicle, entered into on October 19, 2026 as part of the pending business combination (announced June 17, 2026, amended three times). An initial closing issued a note with an original principal amount of $2.41 million (10% original issue discount) and warrants for 201,111 shares at $12.00, in exchange for $2.17 million previously funded by the investor. The notes are fully subordinated to the senior secured financing and cannot receive payments while those notes are outstanding, which limits the investor's recovery position relative to the secured lender.
- · Unsecured notes mature April 15, 2027, extendable to July 15, 2027 on conditions matching the secured notes
- · Subordination Agreement dated October 19, 2026 bars payments on unsecured notes (other than scheduled interest) while secured notes are outstanding, including at maturity, default, or change of control
- · No lien or collateral secures the unsecured notes, unlike the secured notes
- · Unsecured PubCo notes carry a $12.00 initial conversion price, nine-month VWAP reset, and $5.00 floor price
- · Domestication moves SVAQ from the Cayman Islands to Delaware before closing; EigenQ becomes a wholly owned subsidiary of PubCo
- · Additional closing is at a mutually agreed date and subject to conditions, so the full $5.0M is not yet committed
21-10-2026
Innate Pharma S.A. (IPHYF) furnished a Form 6-K dated October 21, 2026, attaching Exhibit 99.1, a press release of the same date. The cover page and signature block identify Jonathan Dickinson, Chief Executive Officer, as signatory. The filing body contains no financial figures, so the substance of the announcement can only be determined from the attached press release, which was not included in the provided content.
- · Registrant files annual reports on Form 20-F (Form 40-F box not checked), consistent with a foreign private issuer status.
- · Commission File Number 001-39084; principal executive office at 117 Avenue de Luminy, 13009 Marseille, France.
- · Exhibit 99.1 (press release dated October 21, 2026) is referenced but its content is not included in the provided filing text.
21-10-2026
Silicon Valley Acquisition Corp. (SVAQ), a Cayman Islands SPAC, filed a Rule 425 communication disclosing an October 19, 2026 Unsecured Purchase Agreement with a special purpose investment vehicle for up to $5,000,000 of subordinated unsecured promissory notes (initial OID-adjusted principal of $2,413,333.33, with up to $2,586,666.67 more at an Additional Closing) and warrants at $12.00 per share, tied to the pending Business Combination with EigenQ, Inc. The notes are unsecured, expressly subordinated to the senior secured financing, and carry interest of 8% cash or 10% PIK. The filing is primarily a financing disclosure that adds leverage and dilution risk layered beneath the existing secured notes, rather than a change to the merger terms themselves.
- · Unsecured Notes mature April 15, 2027, extendable to July 15, 2027 on conditions similar to the Secured Notes
- · Unsecured Notes have no collateral and are fully subordinated to the Secured Notes; no payments of principal, premium, or redemption amounts are permitted while Secured Notes remain outstanding
- · Unsecured Investor's future financing participation rights are limited to a pro rata share and survive repayment of the Secured Notes
- · Unsecured PubCo Warrants are subject to the same $5.00 floor price as Secured PubCo Warrants
- · Unsecured Notes amendments adverse to Secured Note holders require their consent
21-10-2026
Cadeler A/S announced a reminder that the voluntary share exchange offer by Cadeler plc to Cadeler A/S shareholders, tied to the company's redomiciliation from Denmark to the United Kingdom, expires today, 21 October 2026, at 5:00 PM ET / 11:00 PM CEST, unless extended by up to a total of 10 weeks from 22 September 2026 (latest possible expiry 1 December 2026). The offer requires more than 90% of outstanding shares to be validly tendered, so completion is conditional and not assured. The filing contains no financial results, revenue, or other quantitative performance data, so no period-over-period comparison is possible.
- · Offer expiry is subject to Cadeler plc's sole discretion to extend, up to 1 December 2026
- · Acceptance is via DNB Carnegie as receiving agent (email retail@dnb.no or post); Norwegian retail holders with BankID may accept electronically; ADS holders tender via Computershare with Georgeson as information agent
- · Cadeler plc will not accept tenders from Russian or Belarusian nationals/residents or persons where issuance would breach sanctions
- · All current Cadeler board members and executive management will remain in place at Cadeler plc post-redomiciliation; Cadeler plc will become ultimate parent of the Cadeler Group
- · Cadeler is listed on NYSE (CDLR) and Oslo Stock Exchange (CADLR); filed Form F-4 registration statement with the SEC
21-10-2026
Vertical Aerospace Ltd. (EVTWF) announced that its Board of Directors appointed Marc Fontaine as a director effective October 21, 2026, following a proposal from Mudrick Capital Management L.P. under its director appointment rights. Mr. Fontaine is currently CEO of Helsing SAS, the French entity of Helsing, and previously held senior roles at Airbus across commercial aircraft, defence and space, and helicopter businesses. The filing contains no quantitative financial results or period-over-period performance data.
- · Board appointment made on October 20, 2026, effective October 21, 2026
- · Appointment proposed by Mudrick Capital Management L.P. under director appointment rights in the Company's amended and restated memorandum and articles of association
- · Press release announcing the appointment furnished as Exhibit 99.1
- · Company's Annual Report on Form 20-F was filed with the SEC on March 24, 2026
- · Report incorporated by reference into multiple Form F-3 registration statements
21-10-2026
ChipMOS Technologies disclosed via a Form 6-K (filed on TWSE MOPS and furnished to the SEC) that it acquired machinery equipment and related accessories for a total transaction price of NT$1,237,950 thousand, with transactions occurring between 2026/03/15 and 2026/10/21, approved at the President level for manufacturing purposes. The company also disposed of machinery equipment for NT$58,557 thousand, projecting a gain of NT$37,904 thousand from that disposal. The counterparty is K-SHINE ELECTRONIC CORPORATION, which the company states has no relationship with ChipMOS and is not a related party.
- · Transaction period runs from 2026/03/15 to 2026/10/21, approved at President level with no board resolution required
- · Disclosure made under TWSE material information rule Article 4, Paragraph 1, Item 20 for non-related-party equipment transactions exceeding NT$500 million
- · Transaction price was negotiated by mutual agreement referencing market value; no independent appraisal was obtained
- · Acquisition is stated to be for manufacturing purposes
21-10-2026
SVAQ's 8-K (Items 1.01, 2.03, 3.02, 9.01) furnishes a Securities Purchase Agreement dated October 19, 2026 among EigenQ, Inc., SVAQ and an unsecured investor (Buyer/SPV) tied to the pending Business Combination under the June 17, 2026 Business Combination Agreement. The unsecured convertible notes and warrants are subordinated to a September 17, 2026 senior secured financing (Anchor Purchase Agreement), and the agreement imposes reservation, listing, and anti-dilution obligations on the post-closing PubCo. The filing is a deal-structure disclosure: the exhibit contains no reported financial results, and the terms are conditional on the Business Combination closing, with no SVAQ obligations if that closing does not occur.
- · Notes and warrants are unsecured and subordinate to Senior Notes under the September 17, 2026 Anchor Purchase Agreement, with Action Limitations restricting Buyer enforcement while senior notes are outstanding
- · Conversion and exercise price reference is capped at the lower of $5.00 and the then-effective Conversion or Exercise Price for reservation calculations
- · Company must maintain reserved shares at 200% of maximum Conversion Shares and Warrant Shares and seek stockholder approval for authorized share increases if needed
- · Dilutive issuances are restricted where they would breach Nasdaq Rule 5635
- · SVAQ has no obligations under the agreement if the Business Combination does not close; Buyer waives any claim to the Trust Account
- · Buyer identity is left as a blank placeholder [●] in the exhibit provided
21-10-2026
reAlpha Tech Corp. (AIRE) filed an 8-K disclosing that, effective March 9, 2026, its Board approved an updated non-executive director compensation policy totaling $100,000 per director annually, comprising $75,000 in stock and $25,000 in cash. The filing is a routine governance disclosure with no reported financial results, deal activity, or negative developments.
- · Share Awards are issued quarterly on January 30, April 30, July 30 and October 30, with share count set by dividing $18,750 by the 10-day VWAP ending on the grant date
- · Policy approved by the Board upon recommendation of the Compensation Committee; the filing itself was made October 21, 2026, roughly seven months after the stated effective date
- · Common stock trades on Nasdaq under the symbol AIRE; the company is an emerging growth company
21-10-2026
HUTCHMED (China) Ltd filed a Form 6-K for October 2026 furnishing Exhibit 99.1, a press release announcing the closing of its licensing agreement with GSK for KRAS-EGFR antibody conjugate therapy outside China. The filing itself contains no financial figures, and the financial terms of the deal are not disclosed in the body of the 6-K provided.
- · The filing is a Form 6-K for the month of October 2026, Commission File Number 001-37710.
- · HUTCHMED's principal executive offices are at 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.
- · The licensed rights are scoped to territories outside China, with China rights not part of this transaction.
- · The company identifies itself as a foreign private issuer filing under Form 20-F rather than Form 40-F.
21-10-2026
Thermo Fisher Scientific reported Q3 2026 revenue of $12.14 billion, up 9% YoY (6% organic), with GAAP diluted EPS of $4.64 (up 9%) and adjusted EPS of $6.68 (up 15%). GAAP operating margin expanded to 18.6% from 17.4%, while adjusted operating margin rose to 24.5% from 23.3%. Growth was partly acquisition-driven (3 points) and the company completed the divestiture of its microbiology business; the company will provide updated 2026 guidance on the earnings call.
- · Specialty Diagnostics segment revenue declined about 6.5% YoY to $1,098M, and segment margin was 31.0% versus 27.4%.
- · Laboratory Products and Biopharma Services grew about 15% YoY to $6,863M, the largest contributor to growth.
- · Consolidated depreciation expense rose to $307M from $227M, and GAAP operating income was held back by a $244M held-for-sale loss and a $72M gain on sale of a business that are excluded from adjusted results.
- · Interest expense increased to $417M from $347M, and the GAAP effective tax provision rose to $352M from $207M.
- · Nine-month YTD revenue reached $35,136M, up about 8.6% from $32,341M.
21-10-2026
KB Financial Group reported that its largest shareholder, the Korean National Pension Service, reduced its holding from 32,622,276 shares (9.20%) as of August 7, 2026 to 32,576,394 shares (9.18%) as of September 30, 2026, based on the shareholder registry against 354,687,734 total shares. The change is a marginal decline of 45,882 shares, or roughly 0.14% of the position, and total share count was unchanged.
- · Filing is a Form 6-K for the month of October 2026, filed as a foreign private issuer report
- · Shareholding figures are based on the company's shareholder registry as of September 30, 2026
21-10-2026
DRDGOLD reported gold production of 1,307 kg (42,021 oz) for the quarter ended 30 September 2026, up 2% quarter-on-quarter and 10% year-on-year, with gold sold up 14% year-on-year. Revenue rose 31% year-on-year to Rm 2,950.6 million (US$181.2 million), but declined 6% quarter-on-quarter, and operating profit fell 14% sequentially to Rm 1,627.4 million (US$100.0 million) even as it grew 42% year-on-year. Unit costs were mixed: cash operating costs per kg rose 5% year-on-year and all-in sustaining costs per oz rose 15% in US dollar terms, while all-in costs per oz fell 19% quarter-on-quarter.
- · Gold sold was flat quarter-on-quarter (1,324 kg vs 1,322 kg).
- · Sustaining capital expenditure rose 22% QoQ to Rm 119.7 million, and 132% YoY.
- · Tonnage throughput declined 3% QoQ and 5% YoY to 6,170 thousand tonnes.
- · Average gold price received fell 6% QoQ in Rand (R 2,223,112 per kg) and 5% in US dollars (US$4,247 per oz), while rising 24% YoY in US dollars.
- · Cash operating costs per oz rose 6% QoQ to US$1,909 and 13% YoY in US dollars.
- · Average R/US$ exchange rate strengthened to 16.28 from 17.63 a year earlier (down 8% YoY), which inflated the US dollar growth of revenue relative to Rand growth.
21-10-2026
XWELL, Inc. filed a definitive additional-materials supplement (DEFA14A) to its October 8, 2026 proxy statement for a virtual special stockholder meeting on October 28, 2026, correcting the number of shares outstanding as of the October 7, 2026 record date from 9,970,883 to 10,620,883 (an increase of 650,000 shares, or about 6.5%, from restricted stock awards to Board members issued in August 2026 that were inadvertently omitted). The correction does not change the record date, meeting logistics, proposals, required vote, or the Board's recommendation. The filing also restates details of support agreements under which directors, executive officers and American Ventures LLC Series XXIV XWELL agreed to vote in favor of the sale transaction, with the Support Parties collectively holding approximately 26.4% of outstanding shares entitled to vote.
- · Board members and executive officers who hold shares are Support Parties bound to vote in favor of the Purchase Agreement and against alternative transactions, and to be present for quorum at every stockholder meeting.
- · If the Special Meeting is adjourned, prior proxies from Support Parties remain valid without new submissions.
- · Support Parties' transfer restrictions and non-solicitation obligations apply solely in their capacity as stockholders.
- · XWELL is not a party to the Support Agreements but is an express third-party beneficiary.
- · Stockholders who already returned proxies need not take action unless they wish to change their vote.
21-10-2026
Standard BioTools (LAB) filed Amendment No. 1 to its S-4 registration statement on October 21, 2026, for an all-stock reverse merger with clinical-stage biopharma Treeline Biosciences, under which Standard BioTools stockholders are expected to own about 16% and former Treeline holders about 84% of the combined company. The deal is paired with the divestiture of Standard BioTools' mass cytometry business to Element Biosystems and a separate microfluidics sale to ARCHIMED, and Casdin Capital, which owns roughly 23% of LAB, is also a Treeline investor, prompting a special committee review. The filing is a registration document and does not itself report new operating results, so the key figures are deal terms rather than financial performance.
- · Merger Agreement signed June 6, 2026; Element Mass Cytometry Purchase Agreement signed September 30, 2026; Microfluidics Purchase Agreement signed October 4, 2026
- · Merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Code and is accounted for as a reverse recapitalization with Treeline as accounting acquirer
- · Closing of the Merger is not conditioned on the Element divestiture, though the parties expect the two to close substantially concurrently
- · Standard BioTools must use commercially reasonable efforts to monetize its Legacy Businesses (mass cytometry and microfluidics)
- · Special Meeting of Standard BioTools stockholders to approve the share issuance and charter amendment (name change to Treeline Biosciences, Inc. and Reverse Stock Split) is scheduled for a date still to be set (blank in filing)
- · Treeline's preclinical pipeline includes neurology and immunology programs in addition to oncology
- · The filing lists risk factors beginning on page 44 and notes that historical financials going forward will be those of Treeline
21-10-2026
Woodside Energy Group Ltd furnished a Form 6-K on October 21, 2026, attaching its ASX announcement 'Third Quarter 2026 Report' as Exhibit 99.1. The filing itself is a cover document with signature block and exhibit index; the substantive operating and financial figures are contained only in the referenced exhibit, which was not included in the provided content.
- · Filing is a Form 6-K for the month of October 2026, Commission File Number 001-41404
- · Registrant files annual reports on Form 20-F (not 40-F)
- · Exhibit 99.1 is the ASX Announcement dated October 21, 2026, titled 'Third Quarter 2026 Report'
- · Filed with principal executive offices at Mia Yellagonga, 11 Mount Street, Perth, Western Australia
21-10-2026
Alterity Therapeutics Limited filed a Form 6-K on October 21, 2026, submitting a Notice of Annual General Meeting and Proxy Form as Exhibit 99.1. The filing is a procedural governance disclosure with no financial results, transaction, or operational update included in the submitted content.
- · Registrant is a development stage enterprise headquartered at Level 15, 500 Collins Street, Melbourne, Victoria, Australia
- · Filer is a foreign private issuer reporting under Form 20-F annual report obligations
- · The 6-K is incorporated by reference into Form S-8 registrations (333-251073, 333-248980, 333-228671) and Form F-3 registration (333-274816)
- · Filing was signed by Chairman Julian Babarczy on October 21, 2026
21-10-2026
Guardian Metal Resources plc (GMTL) furnished a 6-K dated October 21, 2026, consisting of a contact and advisor directory. The excerpt contains no operational, financial, or transactional disclosure beyond the names and contact details of the CEO, Nominated Adviser, joint brokers, and financial PR firms.
- · Cairn Financial Advisers LLP serves as Nominated Adviser; Berenberg and Tamesis Partners LLP serve as joint brokers; Tavistock provides UK financial PR and Edelman Smithfield provides US financial PR
- · The excerpt does not state the subject matter of the 6-K, and no financial figures, dates of events, or regulatory actions are included
21-10-2026
AITX reported fiscal Q2 2027 (quarter ended August 31, 2026) revenue of $1,985,604, up 5% year-over-year and up 8% sequentially, with a return to sequential and YoY growth. Revenue excluding its largest customer rose 61% YoY to a record $1,627,444, while the largest customer's revenue fell to $358,160 (18% of total, down from 46%). However, gross margin fell to 54% including a $270,987 inventory write-down (67% excluding it, versus 71% in the prior-year quarter), operating expenses for the six months declined only 5%, loss from operations remained at $2,680,396 for the quarter, and the company continues to flag going-concern risk and reliance on external financing.
- · Largest customer began reducing spend in December 2025 as part of its own cost-cutting initiatives; its share fell from 46% to 18% of revenue YoY
- · Management targets monthly operating cash breakeven (excluding debt service and device builds) in January 2027 and all-in cash breakeven in Q2 calendar 2027; these are non-GAAP internal measures
- · Company explicitly warns that achieving these objectives would not establish positive operating cash flow under GAAP, overall profitability, or elimination of need for external financing
- · Results were reviewed but unaudited; the 10-Q was filed October 20, 2026, and the company references ability to continue as a going concern as a risk factor
- · Company is a penny stock (OTC), so the forward-looking statement safe harbor is not available
- · Only one month of the August cost-reduction program is reflected in Q2 results; further savings expected in Q3
21-10-2026
Luma Capital S.A. - SPF filed a Form 13F-HR for the period ending September 30, 2026, disclosing 13 equity positions with a combined reported market value of approximately $121.8 billion (121,783,150 thousand USD as reported in the information table). Largest reported positions include Brookfield Corp (~$9.8B), Amazon (~$19.6B), Berkshire Hathaway Class B (~$10.1B), Markel Group (~$12.0B), and Visa (~$12.2B). The filing is a routine quarterly holdings disclosure; it does not itself report period-over-period changes in holdings, so no growth or decline comparisons can be drawn from this document.
- · Filer is a non-US (Luxembourg) institutional investment manager, SEC file number 028-25956
- · Report covers period ending September 30, 2026; filed October 21, 2026
- · All positions reported with sole investment discretion and no shared or other voting authority indicated
- · Filing does not disclose prior-period holdings, so changes in positions cannot be determined from this document alone
21-10-2026
Elevance Health reported Q3 2026 operating revenue of $50.4 billion, up 0.7% YoY, with diluted EPS of $6.27 (up 17.9%) and adjusted diluted EPS of $6.99, aided by a net non-operating benefit of $1.85 per share. The company raised FY 2026 diluted EPS guidance to at least $22.00 and adjusted diluted EPS guidance to at least $29.00. However, operating gain was flat at $1.3 billion, Health Benefits operating gain fell 27.5%, operating expense rose 9.1%, and medical membership declined 1.1% YoY.
- · Benefit expense ratio improved 70 bp to 90.6%, driven by Medicare Advantage and Individual ACA performance
- · Nine-month operating cash flow of $7.5B vs $4.2B prior year, largely from favorable working capital
- · Nine-month operating margin compressed 120 bp to 3.4%, with operating gain down 25.7% YoY
- · Medicare Advantage membership fell 15.5% YoY, the steepest membership decline among segments
- · Q4 2026 dividend of $1.72 per share declared, payable December 18, 2026
- · Management targets at least 12% adjusted diluted EPS growth in 2027 from a baseline of at least $26.75
21-10-2026
Lufax Holding Ltd furnished a Form 6-K under Exhibit 99.1 announcing that it will report its third quarter 2026 financial results on October 27, 2026. The filing contains no quantitative financial data, and it is signed by CEO Xiang Ji.
- · Third quarter 2026 financial results are scheduled for release on October 27, 2026
- · Filing is a Form 6-K for a foreign private issuer, with Form 20-F as its annual report form
21-10-2026
JinkoSolar Holding Co., Ltd. filed a Form 6-K on October 21, 2026, furnishing a press release (Exhibit 99.1) announcing the results of its 2026 Annual General Meeting of shareholders. The filing is a routine shell report with no financial results, quantitative metrics, or deal terms disclosed in the body of the document.
21-10-2026
Alterity Therapeutics Limited filed a Form 6-K on October 21, 2026, submitting Exhibit 99.1 covering changes to the terms of employment for its Managing Director. The filing is a short administrative notice with no financial results, dollar amounts, or operating metrics disclosed in the body of the document. The specific terms of the employment change are contained only in the referenced exhibit, which is not reproduced in the provided content.
- · Exhibit 99.1 concerns changes to the Managing Director's terms of employment; details are not included in the provided text
- · Filing is incorporated by reference into Form S-8 registrations (File Nos. 333-251073, 333-248980, 333-228671) and Form F-3 (File No. 333-274816)
- · Registrant reports under Form 20-F annual reporting rather than Form 40-F
- · Company principal executive office is located at Level 15, 500 Collins Street, Melbourne, Victoria, Australia
21-10-2026
Nuburu, Inc. (BURUW) entered into an implementation agreement with Tekne S.p.A.'s existing shareholders under which its subsidiary Nuburu Defense LLC will acquire 67.1% of Tekne's share capital for an aggregate price of EUR 5.2 million, of which EUR 1.2 million was paid at signing and EUR 4.0 million is deferred in four EUR 1.0 million installments through March 31, 2027. The agreement also contemplates a recapitalization of Tekne, whose losses as of June 30, 2026 may require urgent measures under Italian Civil Code Articles 2446 and 2447, and an earn-out of EUR 20.0 million payable to the existing shareholders, including a guaranteed minimum of EUR 2.0 million per year. The transaction carries significant financial strain signals alongside the acquisition, as Nuburu has already advanced EUR 27.7 million in shareholder loans to Tekne.
- · Golden Power Authorization was obtained subject to requirements on August 5, 2026, making the Investment Agreement effective
- · Tekne's losses as of June 30, 2026 may trigger urgent equity-strengthening measures under Italian Civil Code Articles 2446 and 2447
- · Earn-Out was reduced from EUR 29.692M to EUR 20.0M, with the Existing Shareholders waiving the difference as part of the recapitalization
- · Nuburu and Nuburu Defense are jointly and severally liable for Earn-Out payments; failure to pay the Guaranteed Annual Minimum within 60 days could trigger acceleration of the full outstanding Earn-Out, recoverable within a further 120 days
- · Security for Deferred Price is an SFE - SocFinEur 7.5% bond (ISIN GB00BNYKP345) held by ADA, to be returned to Nuburu after final installment
- · Purchase and Sale closing was scheduled for October 15, 2026, prior to this filing date
21-10-2026
Entravision Communications appointed Brian Krzanich (former Intel CEO and current Cerence CEO) and Gary Ferrera (former CFO of nine companies) to its Board of Directors, effective October 14, 2026, with Ferrera also joining the Audit Committee and being determined an audit committee financial expert. Directors Fehmi Zeko will step down after the October board meeting following seven years of service, and Gilbert Vasquez, a 19-year director and Audit Committee Chair, will not stand for reelection at the 2027 annual meeting. The board refresh is framed by management as supporting growth of the ATS (advertising technology services) business.
- · Gilbert Vasquez chairs the Audit Committee, so his departure creates a leadership vacancy that Ferrera's audit committee appointment only partly fills
- · Zeko's exit is effective after the October board meeting, while Vasquez's departure is delayed until the 2027 annual stockholder meeting
21-10-2026
Lichen International Ltd (LICN) filed a 6-K/A to confirm completion on October 12, 2026 of a previously announced share transfer agreement dated October 7, 2026, under which its indirect subsidiary Legend Consulting Limited (Legend HK) transferred all issued shares of Bondly Enterprises Limited (the Target) to an unaffiliated Transferee for one Hong Kong dollar. Following completion, the Company no longer holds any equity interest in the Target. The filing reports no financial results, revenue, or valuation figures for the disposed entity.
- · Share transfer agreement signed October 7, 2026 and completed October 12, 2026
- · Filing is incorporated by reference into Form F-3 (File No. 333-291878) and Form S-8 (File No. 333-291376)
- · Filing amends/supplements the October 13, 2026 6-K previously furnished to the SEC
21-10-2026
On October 21, 2026, the Board of Shinhan Bank, a wholly-owned subsidiary of Shinhan Financial Group, resolved to declare an interim cash dividend of KRW 630.67 per common share, totaling KRW 1,000,000,000,000 (KRW 1 trillion), with a record date of November 5, 2026. As sole shareholder, the parent company is entitled to receive the entire dividend amount. The filing is a routine intra-group dividend determination with no reported performance comparisons.
- · Dividend per common share: KRW 630.67
- · Record date for interim dividend: November 5, 2026
- · Parent company is sole shareholder of Shinhan Bank and receives the entire dividend
21-10-2026
Shinhan Financial Group reported that its largest shareholder, Korea's National Pension Service (NPS), reduced its common share holding from 44,370,524 shares (9.45%, as of July 30, 2026) to 43,476,040 shares (9.26%, as of September 30, 2026), based on the shareholder registry closing as of September 30, 2026. The decrease is a reduction of 894,484 shares, or approximately 2.0% of NPS's holding, and about 0.19 percentage points of ownership.
- · NPS remains the largest shareholder of Shinhan Financial Group after the reduction
- · The disclosure is based on the shareholder registry closing as of September 30, 2026
21-10-2026
Hotel101 Global Holdings Corp. (Nasdaq: HBNB) signed definitive binding agreements for a country-wide joint venture with IGI Holding affiliates WNTR Property and WNTR Hospitality to expand into Egypt, its first African market, starting with Hotel101-Cairo West, an approximately 750-room hotel on a 15,984 sqm site in 6th of October City, Giza, expected to be completed by 2029 with a total project value of 5.465 billion Egyptian pounds (US$102.09 million). The development remains subject to customary governmental, regulatory, corporate and other approvals, and the filing provides no comparative financial period data.
- · Project value converts to approximately US$102.09 million, using the filing's stated exchange rate; the EGP figure is the primary reported value
- · Hotel101-Cairo West is expected to be one of the top 3 largest hotels by room count in Cairo
- · Site is roughly ten minutes from the Giza Pyramids and the Grand Egyptian Museum, with access to Sphinx International Airport and the Cairo Ring Road
- · The business model is designed to generate revenue twice: from advance sale of condotel units during construction and from long-term recurring hotel operations
- · Expansion is expected to be driven mainly by joint ventures and, later, license agreements with local developers
- · Forward-looking risks flagged include joint venture partner interests, project cost and completion risk, deferred payment schemes and customer default risk, and foreign regulatory compliance
21-10-2026
Cenntro Inc. (CENN) filed Amendment No. 1 to its October 15, 2026 Form 8-K solely to add Exhibit 5.1, a legal opinion from Wendot Law Group (its newly engaged Nevada counsel), and the related Exhibit 23.1 consent, in connection with its at-the-market (ATM) offering. The amendment does not change any other disclosure in the original filing and contains no financial results or quantitative performance data.
- · Amendment relates to the original Form 8-K filed with the SEC on October 15, 2026
- · Incorporated by reference into Form S-3 registration statement (File No. 333-292994)
- · Exhibit 5.1 (legal opinion) and Exhibit 23.1 (consent) tied to the ATM offering
- · Event date of earliest report is October 9, 2026; signature dated October 20, 2026
21-10-2026
Helio Corp /FL/ (HLEO), a Berkeley, CA-based company classified under guided missiles, space vehicles and parts (SIC 3760), filed an S-1 registration statement with the SEC on October 21, 2026 (SEC file no. 333-299557), indicating a proposed securities offering. The filing's extracted content is primarily XBRL tagging metadata covering fiscal periods through July 31, 2026, with references to convertible preferred stock (Series A through D), convertible notes, related-party notes payable and subsequent-event notes, but the operative narrative, offering size, pricing, and use of proceeds are not present in the excerpt provided. Financial performance (revenue, net income, cash position) cannot be assessed from this content, so the filing's balance of positive and negative developments cannot be determined.
- · Registration statement S-1 filed October 21, 2026 under SEC file number 333-299557; the 'IPO Registration' preliminary classification is consistent with the form type
- · Fiscal year end is October 31 (FYE 1031); reporting periods referenced run through July 31, 2026
- · Outstanding capital structure includes Series A, B, C and D convertible preferred stock, plus common stock and common stock to be issued
- · Multiple convertible note and promissory note agreements are referenced, including related-party notes (two officers, the CEO, and an individual named James Byrd) and notes with a maturity date of June 20, 2026
- · Debt disclosures reference notes from unrelated parties with interest/terms ranges and a subsequent-event note agreement with a September 30, 2026 date
- · Company has undergone two name changes (Stirling Bridge Group Inc in 2022; WEB3 Corp in 2023)
- · Excerpt does not include offering size, price range, underwriters, use of proceeds, or audited financial results; these should be verified in the full prospectus
21-10-2026
Churchill Capital Corp XI (CCXI) filed a Form 425 containing a CNBC interview transcript in which Agility Robotics CEO Peggy Johnson discusses the proposed business combination between Churchill XI and Agility Robotics, alongside the company's product and commercial strategy. Johnson highlights Digit 5, slated for release next year, which is designed to operate outside fenced work cells alongside humans, and cites $300 million of booked multi-year orders and a manufacturing facility built for 10,000 robots per year. The filing does not disclose transaction valuation, deal terms, or financial results, and the transcript contains no discussion of risks, shortfalls, or flat metrics.
- · Digit 5 is expected to be released next year and is designed to work outside fenced work cells alongside humans
- · Digit robot uses LIDAR sensors plus RGB and IR camera pairs positioned around the robot for 360-degree human detection
- · Robot stops when a human approaches within a set radius and powers down to the ground at very close proximity
- · Agility offers both robot-as-a-service monthly fees (including hardware, software, maintenance, and upgrades) and outright purchase
- · Stated transaction-related disclosure is limited to the interview; no deal valuation, structure, or timing is provided in this filing
21-10-2026
ClimateRock (CLRWF), a SPAC-structured company, reported a Q2 2026 net loss of $124,477 (vs. $172,412 in Q2 2025) and a six-month net loss of $292,815 (vs. $357,450). Trust Account assets fell to $103,568 from $160,938 at year-end 2025 following $60,032 of shareholder redemptions, and total shareholders' deficit widened to $(10,588,448). Results are mixed: losses narrowed year over year, but the company remains deeply insolvent on a balance-sheet basis, with current liabilities of $8,231,018 against only $5,070 of unrestricted cash.
- · Trust Account redemptions of $60,032 in six months 2026 compare with $24,663,840 in six months 2025, reflecting a sharp slowdown in shareholder redemptions
- · Working capital deficit: current liabilities of $8,231,018 exceed current assets of $5,070 by roughly $8.2 million
- · Related-party funding continues to fund operations: $218,376 of related-party loan proceeds and $60,000 of accrued administrative service fees in six months 2026
- · Redemption value per Class A share rose to $13.26 at June 30, 2026 from $13.03 at December 31, 2025, reflecting Trust dividend accretion
- · Deferred underwriting commission of $2,362,500 remains payable and is classified as non-current
21-10-2026
ClimateRock (CLRWF), a SPAC-style blank-check company, reported a net loss of $168,338 for the three months ended March 31, 2026, versus a net loss of $185,038 in the prior-year quarter, as lower dividend income on its Trust Account ($1,418 vs. $307,887) offset a reduction in operating costs (formation and operating costs of $139,756 vs. $462,925). Total assets rose slightly to $167,726 from $166,608 at December 31, 2025, but shareholders' deficit widened to $(10,462,727) from $(10,292,971), and current liabilities increased to $8,105,597 from $7,936,141, reflecting continued reliance on related-party loans and accrued liabilities.
- · Trust Account balance rose to $162,356 from $160,938 at December 31, 2025, with redemption value of $13.14 per share at March 31, 2026 versus $13.03 at December 31, 2025.
- · Cash fell to $5,370 from $5,670 at year-end, and the company funded operations through $50,831 of related-party loan proceeds in Q1 2026.
- · Accumulated deficit grew to $(10,462,936) from $(10,293,180), and the company had no monthly extension fees in Q1 2026 versus $150,000 in Q1 2025.
- · Non-redeemable shares reported EPS of $(0.08) in Q1 2026 versus $(0.14) in Q1 2025, while redeemable shares reported $0.03 versus $0.04.
21-10-2026
Farnam Financial LLC (Phoenix, AZ) filed a Form 13F-HR for the quarter ended September 30, 2026, reporting an equity and ETF portfolio of 58 holdings with a total reported value of approximately $135,476,927 (thousands-based reporting). The portfolio is concentrated in broad-market index ETFs, fixed-income ETFs (including defined-maturity bond ETFs), and large-cap individual stocks such as Apple, Microsoft, Nvidia, Amazon, and Berkshire Hathaway Class B. No quarter-over-quarter comparison is provided in this filing, so no period-over-period change can be calculated.
- · Largest individual equity positions by reported value include Apple (~$65.0M per information table), Microsoft (~$41.1M), Nvidia (~$7.5M) and Amazon (~$6.5M), with Berkshire Hathaway Class B among the larger single-name holdings (~$7.0M).
- · Portfolio includes a significant allocation to defined-maturity bond ETFs (iShares iBonds and Invesco BulletShares series maturing 2026 through 2034), indicating a fixed-income laddering component.
- · Filing is signed by Aryn Sands on October 20, 2026, with a stated filing manager location in Reno, NV; amendment status is original (not 13F-HR/A).
21-10-2026
Ecopetrol S.A. (NYSE: EC) furnished a Form 6-K for October 2026 under Rule 13a-16. The filing is a cover-page and signature submission only, with no financial results, operational data, or substantive disclosures included in the text provided. The 6-K is signed by CFO Alfonso Camilo Barco and dated October 20, 2026, with a filing date of October 21, 2026.
21-10-2026
Thayer Financial, L.L.C. (Hickory, NC; CIK 0002100981) filed a Form 13F-HR for the quarter ended September 30, 2026, reporting 32 holdings with an aggregate reported market value of approximately $111.07 million (111069815 in thousands, per the filing's value convention). The portfolio is dominated by diversified ETFs spanning U.S. and international equity, fixed income, and sector exposures, with a smaller set of single-stock positions including Apple, NVIDIA, Duke Energy, and Lowe's.
- · Single-stock exposure is small and concentrated in a handful of names: Apple (1,780 shares), NVIDIA (978 shares), Lowe's (2,366 shares), and Duke Energy (5,634 shares)
- · Holdings are almost entirely ETFs with sole investment and voting discretion (SOLE), indicating a passive, index-oriented allocation approach
- · Filing is signed by Aryn Sands as agent, dated October 20, 2026, with a filing date of October 21, 2026, and is a standard quarterly institutional holdings disclosure
21-10-2026
STARRY SEA ACQUISITION CORP (SSEAR), a Cayman Islands blank-check company, filed its Third Amended and Restated Memorandum and Articles of Association (Exhibit 3.1 to an 8-K), adopted by special resolution and effective October 19, 2026. The filing sets the authorized share capital at US$50,000 divided into 500,000,000 ordinary shares of par value US$0.0001 each, and governs the Business Combination, Trust Account, and extension mechanics. The excerpt provided contains no quantified financial performance comparison and no completed acquisition terms.
- · Governing documents were adopted by special resolution dated and effective October 19, 2026, and the 8-K was filed October 21, 2026
- · Registered office is with Maples Corporate Services Limited, Ugland House, Grand Cayman
- · Business Combination must be with target business(es) having aggregate fair market value of at least 80% of Trust Account assets while NASDAQ-listed, and cannot be solely with another blank-check company
- · Extensions and a Deadline Date are governed by Article 48.7, which is referenced but not reproduced in the excerpt
- · Filing items include 1.01 (material agreement), 5.03 (amendments to articles), 5.07 (shareholder vote), 8.01 (other events), and 9.01 (exhibits)
21-10-2026
Olenox Industries Inc. (NASDAQ: OLOX) announced it completed the acquisition of 100% of Wildboy Holdings, Ltd. and IPD Industries, Inc. for a purchase price of US$21.7 million, paid almost entirely in Series F preferred stock convertible into common shares, subject to conversion limitations and lock-up provisions. The Wildboy assets add a natural gas processing facility (up to 144 MMcf/d) and roughly 184,785 acres in British Columbia with 56.8 Bcf of proved developed reserves, while IPD adds a 100 MW self-generator registration near Pecos, Texas. The deal advances the company's gas-to-power-to-compute strategy, though the filing provides no financial results, revenue contribution, or pro forma impact, and the power-generation opportunity remains contingent on financing, equipment, gas supply agreements, and approvals.
- · Consideration is convertible into common stock subject to conversion limitations and lock-up provisions, creating potential future dilution
- · Management says the structure preserves near-term cash, but no cash balance, debt, or financing commitments for development are disclosed
- · The Waha Hub (West Texas) is cited as the location of the power-development platform
- · Forward-looking statements flag risks including integration, reserve accuracy, financing availability, permit receipt and gas price volatility
21-10-2026
Personalis, Inc. (PSNL) presented an all-hands employee FAQ on October 20, 2026 regarding its pending business combination with TempusAI, Inc. (Tempus), filed under Rule 425. The transaction is expected to close in late 2026, subject to remaining closing conditions. Outstanding Personalis shares will convert into Tempus Class A common stock, cash, or a combination at Tempus' election, and the current ESPP offering period ends October 30, 2026. No quantitative financial results, exchange ratio, or deal value are disclosed in this document.
- · Open enrollment for Personalis benefits runs November 2 to November 13, 2026, with elections effective January 1, 2027
- · 401(k) contributions will be temporarily paused for the rest of 2026 if the deal closes before year-end
- · Vested in-the-money options are cashed out for net stock consideration; out-of-the-money options are cancelled without consideration
- · Unvested in-the-money options and RSUs convert into Tempus equity awards with the original vesting schedule preserved
- · Shareholder approval of the merger agreement is required; the proxy statement/prospectus and Form S-4 are pending with the SEC
- · Transaction also involves a Schedule 13E-3 jointly filed by Tempus, Personalis and certain affiliates, indicating a going-private component
21-10-2026
Beacon Topco, Inc. filed Amendment No. 4 to its Schedule TO to report final results of its issuer tender offer. The offer expired at 5:00 p.m. New York time on October 19, 2026, with 920,605 Shares properly tendered and not withdrawn. Because tendered Shares did not exceed the $15 million aggregate purchase price cap, no proration applied, and the company accepted all tendered Shares for an aggregate purchase price of approximately $6.1 million (excluding fees and expenses), representing approximately 20.28% of outstanding Shares.
- · Offer was not oversubscribed in dollar terms, so no proration was required and all tendered Shares were accepted
- · Offer documents were dated September 15, 2026; the Schedule TO was originally filed on September 15, 2026
- · Amendment is marked as the final amendment reporting the results of the tender offer
21-10-2026
Apex Critical Metals Corp. (APXCF) filed a Form 6-K for October 2026 that submits two consent exhibits: Exhibit 99.1 (Consent of Robin J. Wilson) and Exhibit 99.2 (Consent of Jeremy Hanson). Both are incorporated by reference into the company's Form F-10 registration statement (File No. 333-298319). The filing contains no financial results, operational metrics, or transaction terms.
- · Filed under Form 40-F multijurisdictional disclosure framework; company checked Form 40-F rather than Form 20-F
- · Commission File Number 001-42949; principal executive office in Vancouver, British Columbia
- · Signed by CFO Nathan Steinke, dated October 20, 2026
21-10-2026
Adial Pharmaceuticals filed an amended 10-Q/A for the period ended June 30, 2026, reporting a Q2 net loss of $51,989 thousand (versus $1,958 thousand in Q2 2025) driven primarily by a $46,185 thousand acquired in-process research and development charge tied to the Azora Therapeutics acquisition, alongside a $6,054 thousand loss on extinguishment of Azora convertible notes. Cash and cash equivalents rose to $28,712 thousand from $5,881 thousand at December 31, 2025, supported by a $26,800 thousand private placement of pre-funded warrants and $5,282 thousand of cash assumed in the acquisition, while stockholders' deficit widened to $(38,377) thousand from positive $5,277 thousand. Operating cash burn remained modest at $7,975 thousand for the six months versus $3,335 thousand a year earlier, though general and administrative expenses rose sharply to $5,400 thousand in Q2 from $1,150 thousand.
- · Series A convertible preferred stock (temporary equity) of $38,533 thousand was issued as acquisition consideration, and 12,930,601 preferred shares are potentially dilutive
- · Milestone warrant rights liability of $23,812 thousand was recorded, with a Q2 fair value gain of $8,280 thousand and financing expense of $2,067 thousand
- · Total liabilities rose to $28,933 thousand from $1,397 thousand, with accounts payable up to $2,624 thousand and accrued expenses up to $2,497 thousand
- · Net liabilities acquired from Azora were $(4,682) thousand; the acquired in-process R&D of $46,185 thousand is expensed rather than capitalized
- · Operating cash burn increased 139% year over year for the six months, even as R&D spending declined 41% (from $1,479 thousand to $873 thousand)
- · Accumulated deficit reached $(143,984) thousand versus $(89,972) thousand at year-end 2025
21-10-2026
Aya Gold & Silver Inc. furnished a Form 6-K for October 2026 attaching an updated Preliminary Economic Assessment (PEA) for its Boumandine project, filed under NI 43-101 (Exhibit 99.1). The filing itself contains no financial results, quantitative metrics, or period-over-period comparisons; the substantive content lies in the attached technical report, which is not reproduced in the filing text provided.
- · Filing made under Form 40-F multijurisdictional disclosure system, with commission file number 001-43230
- · Registrant's principal executive office is at 1320 boulevard Graham, Suite 132, Mont-Royal, Quebec, Canada
- · Signature date (Aug 5, 2026) predates the stated October 2026 filing month and the October 21, 2026 filing date, a discrepancy worth noting
21-10-2026
One River Asset Management, LLC (Stamford, CT; CIK 0001616336) filed its Form 13F-HR for the quarter ended September 30, 2026, reporting 183 holdings entries with an aggregate reported value of $116,523,351 (table value in thousands, i.e., approximately $116.5 billion). The filing is dominated by large-cap technology, index-level and options positions, with the largest single entries being short put positions on the Invesco QQQ Trust and the iShares MSCI ETF, alongside extensive call and put activity across mega-cap names such as NVIDIA, Apple, Microsoft, Meta and Alphabet. The filing contains no period-over-period comparison data, so performance trends cannot be assessed from this document alone.
- · Holdings are heavily weighted toward options (calls and puts) across most listed names, with the largest dollar exposures in index ETF puts (iShares MSCI ETF and Invesco QQQ Trust) rather than common equity.
- · The filing reports 'SOLE' investment discretion for all entries, with no shared or other-manager voting authority reported.
- · The filing lists a former company name (Peters Capital Group LLC, renamed August 8, 2014) and a filing-manager file number 028-23477.
- · The filing contains no period-over-period comparison data; quarter-over-quarter changes in holdings cannot be derived from this document alone.
21-10-2026
PDS Biotechnology Corporation (Nasdaq: PDSB) filed a Form 8-K under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits) disclosing that on October 20, 2026 it updated its corporate presentation deck, which is furnished as Exhibit 99.1. The filing contains no financial results, quantitative metrics, or regulatory actions, and the substance of the update is not described in the body of the filing.
- · Filing relates to the company's corporate presentation (Exhibit 99.1), dated October 2026, with the update made on October 20, 2026
- · Common stock (par value $0.00033) trades on The Nasdaq Capital Market under the symbol PDSB
- · Company is headquartered at 303A College Road East, Princeton, NJ 08540; Commission File Number 001-37568
21-10-2026
Greenbriar Sustainable Living Inc. (GEBRF), a Coquitlam, British Columbia-based foreign private issuer, furnished a Form 6-K on October 21, 2026 under Rule 13a-16, attaching as Exhibit 99.1 a news release dated October 20, 2026. The filing itself is a cover document and signature page; the substantive content resides in the referenced news release, which was not included in the provided text. No financial figures, performance metrics, or named initiatives are disclosed in the material provided.
- · Filing covers the month of October 2026 and is signed by CEO Jeff Ciachurski on October 20, 2026
- · Attached Exhibit 99.1 is a news release dated October 20, 2026, whose contents are not included in the provided filing text
- · Company checked Form 20-F (not Form 40-F) as its annual report form, identifying it as a foreign private issuer
- · Commission File No. 000-56391; principal executive office at 632 Foster Avenue, Coquitlam, British Columbia, Canada V3J 2L7
Get daily alerts with 11 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 50 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US SEC Filings Daily Market Digest
🇺🇸 More from United States
View all →October 22, 2026
US Pre-Market SEC Filings Roundup — October 22, 2026
US Pre-Market SEC Filings Roundup
October 21, 2026
US Pre-Market SEC Filings Roundup — October 21, 2026
US Pre-Market SEC Filings Roundup
October 21, 2026
S&P 500 Financials Sector SEC Filings — October 21, 2026
S&P 500 Financials Sector SEC Filings
October 21, 2026
S&P 500 Consumer Staples Sector SEC Filings — October 21, 2026
S&P 500 Consumer Staples Sector SEC Filings